uniQure (Nasdaq: $QURE) Stock Hub: AMT-130, the FDA Reversal and the Q3 2026 BLA Path

Executive answer: what is the QURE story now?

1. Company profile: from HEMGENIX pioneer to AMT-130 special situation

uniQure is one of the longest-established publicly traded gene-therapy companies. The company built its scientific identity around adeno-associated viral vectors, internal manufacturing, liver-directed gene delivery and later direct-to-brain administration. Its history includes Glybera, the first gene therapy approved in Europe, and etranacogene dezaparvovec, now commercialized by CSL Behring as HEMGENIX for hemophilia B.

That history matters because uniQure is not a newly assembled platform built around one early clinical program. It has already moved a gene therapy from discovery through global development, regulatory review and approval. HEMGENIX validated important components of vector design, process development, long-term follow-up and commercial manufacturing. However, uniQure licensed commercial rights to CSL Behring and later sold most of its royalty economics, so HEMGENIX is no longer the core valuation engine.

The company’s present value is overwhelmingly linked to AMT-130 in Huntington’s disease. This concentration has advantages and disadvantages. It gives investors a clear catalyst map and a potentially transformational asset in a devastating neurological disease with no approved treatment that slows progression. It also means a regulatory rejection, manufacturing problem or disappointing confirmatory design could impair the majority of the equity story.

Beyond AMT-130, uniQure has two active clinical programs with independent value: AMT-260 for refractory mesial temporal lobe epilepsy and AMT-191 for Fabry disease. AMT-162 in SOD1-ALS was discontinued after a dose-limiting toxicity and an unfavorable review of preliminary safety and efficacy. The discontinuation shows that uniQure is willing to terminate a program, but also reinforces the platform-wide reality that CNS and systemic AAV programs can encounter serious safety limits.

2. Current pipeline snapshot

The active pipeline is therefore narrower than a superficial review may suggest. AMT-130 is close to a regulatory filing. AMT-260 is early but has a potentially differentiated neurosurgical mechanism. AMT-191 has powerful biochemical activity but a complicated dose and liver-safety profile. AMT-162 should be treated as a historical lesson, not hidden inside an “active pipeline” count.

3. Huntington’s disease and the unmet need

Huntington’s disease is an inherited, progressive neurodegenerative disorder caused by an expanded CAG repeat in the HTT gene. The mutation produces toxic forms of huntingtin protein, including mutant huntingtin and exon 1 fragments, that impair neuronal function and eventually drive widespread brain degeneration.

Patients may develop chorea, rigidity, impaired coordination, cognitive decline, psychiatric symptoms and loss of functional independence. Because the mutation is autosomal dominant, children of an affected parent have a 50% chance of inheriting it. Genetic testing can identify mutation carriers years or decades before overt disease.

Available therapies are symptomatic. They can reduce chorea, depression, irritability or other manifestations, but they do not clearly slow the underlying neurodegenerative process. This is why a credible disease-modifying effect can carry enormous clinical and commercial value even if the treatment requires a complex neurosurgical procedure.

The challenge is measurement. Huntington’s progresses slowly and heterogeneously. Short studies may not cleanly distinguish treatment effect from natural variability. Composite measures such as the composite Unified Huntington’s Disease Rating Scale combine motor, cognitive and functional domains, but interpreting an uncontrolled or externally controlled study requires careful matching and sensitivity analyses.

4. How AMT-130 works

AMT-130 is a one-time investigational gene therapy delivered directly into the striatum through MRI-guided neurosurgical infusion. The product uses an AAV5 vector carrying a microRNA designed to reduce expression of the huntingtin gene. The goal is durable lowering of both full-length huntingtin and the highly toxic exon 1 fragment in brain regions central to Huntington’s pathology.

The therapy does not distinguish between mutant and wild-type huntingtin. That creates a core biological trade-off. Lowering mutant huntingtin could slow disease, but excessive suppression of normal huntingtin may create theoretical or long-term risks because the normal protein has important cellular functions. Dose selection must therefore balance sufficient knockdown with preservation of safety.

Direct striatal administration is both a strength and a weakness. It places therapy in the region most affected early in Huntington’s and may support broad brain distribution through vector transport and exosome-mediated spread. But it requires specialized neurosurgery, bilateral catheter placement, hospital resources and post-procedure monitoring. The commercial model would resemble a small number of expert treatment centers rather than conventional outpatient prescribing.

5. The Phase I/II program: U.S. and European studies

The AMT-130 development program combines U.S. and European Phase I/II studies in patients with early manifest Huntington’s disease. The U.S. trial enrolled low-dose and high-dose cohorts with imitation-surgery controls, while the European study used an open-label design. Control participants in the U.S. study could cross over to active treatment after a defined period if eligible.

The integrated program was designed primarily to assess safety, tolerability, biomarker changes and preliminary efficacy. It was not originally powered like a conventional Phase III randomized trial. That design is the origin of both the program’s opportunity and its regulatory controversy.

On the positive side, the studies generated multi-year follow-up from a one-time treatment and included a limited internal surgical-control experience. On the negative side, most long-term efficacy interpretation depends on comparison with externally matched natural-history patients. External controls can be valuable in rare diseases, but they are vulnerable to hidden differences in patient selection, disease stage, site effects, assessment frequency and missing data.

uniQure used the Enroll-HD natural-history database and criteria-matched external controls to compare disease progression. The company also conducted multiple sensitivity analyses intended to show that the result was robust across matching methodologies and assumptions. FDA’s shifting view of that evidence became the defining story of 2025–2026.

6. The AMT-130 efficacy narrative

The central clinical claim is that high-dose AMT-130 materially slowed disease progression over three years compared with matched external controls. uniQure’s topline analysis focused on cUHDRS and Total Functional Capacity, alongside motor, cognitive and biomarker measures.

The cUHDRS combines total motor score, symbol digit modalities, Stroop word reading and Total Functional Capacity. Because Huntington’s affects multiple domains, a composite can be more sensitive to overall change than a single measure. Total Functional Capacity is especially clinically meaningful because it reflects a patient’s ability to work, manage finances, perform domestic tasks and live independently.

The company has described the high-dose three-year result as approximately 75% slowing of progression on cUHDRS versus the matched natural-history control, with supportive effects on TFC. Neurofilament light chain, a marker of neuronal injury, initially rises after neurosurgical administration but later returns toward or below baseline, supporting the view that the procedure causes a temporary injury signal followed by stabilization.

These results are highly encouraging, but interpretation requires discipline. The study is small. The external control is not randomized concurrently. The high-dose cohort contains fewer patients than a normal pivotal study. Composite outcomes can be influenced by baseline differences and missing data. The durability of apparent benefit beyond three years remains important, especially for a one-time intervention.

The correct conclusion is not that the data are weak. The correct conclusion is that the data are strong enough to create a credible accelerated-approval argument, yet unconventional enough that regulatory acceptance cannot be assumed.

7. Safety profile and the 2022 pause

AMT-130 requires invasive neurosurgery and direct brain infusion, so safety must be divided into procedure-related events and vector-related biology. Common adverse events have included effects associated with surgery and hospitalization. In 2022, uniQure voluntarily paused enrollment after suspected unexpected serious adverse reactions in three European patients, including neurological complications.

The company conducted a safety review, modified management procedures and resumed enrollment. Later follow-up suggested that the safety profile was manageable, with no new drug-related serious adverse events reported after December 2022 through the company’s later updates.

This history is relevant for two reasons. First, AMT-130 has already survived a significant clinical safety review and continued development. Second, a commercial label may require detailed risk management around surgery, immunosuppression, imaging, neurological monitoring and center qualification.

Accelerated approval would not eliminate the need for long-term observation. Patients receiving integrating or persistent genetic interventions are followed for years. uniQure must monitor potential neuroinflammation, changes related to non-selective huntingtin lowering, vector durability and any delayed neurological consequences.

8. Regulatory timeline: from alignment to shock to reversal

This sequence is almost unprecedented in its volatility. The same agency first accepted the broad concept, then rejected the evidentiary package, then reopened the filing path. The reversal may reflect additional analyses, evolving internal review, clarification of the confirmatory-study framework, or changes in how FDA weighed the urgency of Huntington’s disease against uncertainty in external controls.

What matters now is the written and operational outcome, not speculation about internal agency politics. The June 2026 disclosure was incorporated into a securities filing: FDA stated that the three-year analysis could serve as the primary BLA basis. That is a meaningful regulatory fact. It is not an approval promise.

9. The confirmatory-study requirement

Before submission, FDA is seeking alignment with uniQure on the confirmatory study design. The agency is considering a concurrent standard-of-care control that would not include a sham surgical procedure. FDA expects the confirmatory study to be underway before approval of the BLA and will determine during review whether that condition has been met by the action date.

This condition is central. Accelerated approval allows approval based on a surrogate or intermediate endpoint reasonably likely to predict clinical benefit, but the sponsor must verify benefit after approval. In the AMT-130 case, the confirmatory study may also serve as protection against uncertainty created by the externally controlled Phase I/II evidence.

A non-sham concurrent control could be more ethical and easier to enroll than a blinded sham-neurosurgery trial. Patients would know whether they received gene therapy, however, which may introduce assessment bias. The design must address endpoint objectivity, site effects, baseline balance and the timing of crossover or rescue treatment.

The most important near-term questions are:

• How many patients will the confirmatory study enroll?
• Will the control arm receive standard of care alone?
• What will be the primary endpoint and follow-up duration?
• Will FDA require cUHDRS, TFC, a biomarker or a hierarchical combination?
• What does “underway” mean at the action date: first patient dosed, active sites or meaningful enrollment?
• Can uniQure launch commercially while a large confirmatory trial is still recruiting?

10. U.S. BLA and UK MAA strategy

uniQure plans to submit a U.S. BLA for AMT-130 in Q3 2026. A complete submission must include clinical data, external-control analyses, manufacturing validation, device and surgical procedure information, long-term follow-up plans, proposed labeling and confirmatory-study documentation.

The company also plans a UK Marketing Authorization Application in Q3 2026 after a pre-submission meeting with the MHRA. The UK pathway provides regulatory diversification. A favorable UK review could create the first commercial market even if the U.S. path slows, while a negative outcome could expose shared concerns about evidence or manufacturing.

European Union strategy is less clearly defined in current guidance. Huntington’s disease is a global market, but sequential regulatory submissions may be necessary because uniQure must allocate resources to the U.S., UK, confirmatory study and launch preparation.

The filing window itself is a catalyst, but BLA acceptance will be more important. If accepted, investors will look for priority-review status, a target action date and whether FDA plans an advisory committee. A public AdCom could amplify debate over external controls, clinical meaningfulness, durability and surgical risk.

11. Commercial opportunity and launch architecture

Huntington’s disease is rare but not ultra-rare. The diagnosed population across the U.S. and Europe is large enough to support a substantial specialized product if clinical benefit is accepted. Mutation carriers can be identified through genetic testing, but the initial AMT-130 label is likely to focus on early manifest patients matching the clinical program.

The product would require treatment at qualified neurosurgical centers. Commercial adoption depends on a coordinated pathway involving neurologists, genetic counselors, imaging, neurosurgery, hospital pharmacy, payer approval and long-term follow-up. The number of treatment centers may be limited initially, which can create a bottleneck but also keeps the commercial organization focused.

Pricing is unknown. One-time neurological gene therapies can support high prices, but payers will scrutinize durability, procedure risk and the uncertainty of accelerated approval. Outcomes-based agreements or staged payments may be considered, particularly if the confirmatory study is incomplete at launch.

The launch curve may be shaped by a backlog of well-characterized early manifest patients, followed by slower steady-state referrals. Some patients may delay treatment because of the invasive procedure, irreversible dosing and uncertainty about long-term wild-type huntingtin lowering. Others may accept meaningful risk because the disease is progressive and no disease-modifying alternative exists.

12. Manufacturing and delivery risk

AMT-130 manufacturing requires consistent AAV5 vector production, validated potency assays, control of capsid quality and reproducible fill-finish. The BLA must demonstrate that clinical material is comparable to the intended commercial process.

uniQure has deep AAV manufacturing experience, but its operating model changed after divestitures and restructuring. The company transferred a Lexington manufacturing facility and later reworked relationships with Genezen and CSL Behring. HEMGENIX supply commitments are transitioning to a direct CSL–Genezen relationship, reducing uniQure’s operational burden but also changing the internal manufacturing footprint.

The administration procedure is equally important. Catheter placement, MRI guidance, infusion rate and targeting must be standardized across centers. A therapy can have an approved vector yet fail commercially if procedural variability produces inconsistent distribution or unacceptable complications.

Center certification and surgeon training may therefore become part of the label and risk-management plan. This creates a high barrier to entry, but also limits the speed of launch.

13. Financial position and dilution framework

uniQure’s balance sheet is one of the strongest in small/mid-cap gene therapy. The company raised approximately $404 million net through public offerings and pre-funded warrants in 2025, ending that year with $622.5 million. This financing created significant dilution, but it also removed the immediate need to fund a BLA and launch from a weak negotiating position.

The runway into the second half of 2029 is based on the current operating plan. A large confirmatory study, accelerated commercial build, manufacturing investment or additional global submissions can raise spending above assumptions. Still, uniQure is not facing the near-term survival financing risk common among development-stage biotech companies.

Dilution risk is therefore medium rather than high. The company has enough cash to reach several major catalysts. Future equity issuance becomes more likely if AMT-130 is approved and launch investment expands, or if AMT-260 and AMT-191 progress into larger trials. The ideal sequence is regulatory de-risking first, capital raising later at a higher valuation if necessary.

14. HEMGENIX legacy: proof of capability, limited economics

HEMGENIX, originally developed by uniQure as etranacogene dezaparvovec, is an approved AAV5 gene therapy for hemophilia B. CSL Behring acquired global commercialization rights through a major licensing transaction.

The program validates uniQure’s ability to design and develop an AAV therapy that reaches approval. It also provides regulatory and manufacturing credibility when evaluating AMT-130. However, investors should not model HEMGENIX as if uniQure retained full product economics.

In May 2023, uniQure entered into a royalty-financing agreement with HemB SPV, L.P. and received $375 million upfront in exchange for rights to the lowest royalty tier on certain current and future HEMGENIX net sales. uniQure retained other contractual economics, including certain milestone rights and royalty participation outside the transferred tier. In 2026, agreements with CSL and Genezen ended uniQure’s remaining supply and minimum-purchase commitments after delivery of specified batches, with CSL moving to a direct Genezen supply relationship.

This simplifies uniQure’s operations and removes manufacturing obligations that no longer fit the AMT-130-centered strategy. HEMGENIX should be treated as platform validation and modest legacy economics—not the primary source of future value.

15. AMT-260 in refractory mesial temporal lobe epilepsy

AMT-260 is a gene-silencing therapy for refractory mesial temporal lobe epilepsy. The program uses an AAV9 vector carrying microRNA designed to suppress aberrant expression of GRIK2, which encodes the GluK2 subunit of kainate receptors in the hippocampus.

Refractory MTLE can cause frequent seizures, cognitive decline, injury and reduced life expectancy. Surgical resection or laser ablation may help some patients, but only a small percentage of eligible patients undergo surgery. AMT-260 seeks to reduce pathological excitability without removing brain tissue.

uniQure acquired the program through Corlieve Therapeutics in 2021. The GenTLE Phase I/IIa study has an open-label dose-escalation part followed by an expected randomized proof-of-concept component. The first cohort included six patients, and enrollment in a second six-patient cohort was underway in 2026.

The first treated patient showed a reported 92% reduction in seizure frequency through five months, without a serious safety event in the initial update. That single-patient result is interesting but not sufficient to establish efficacy. Epilepsy frequency can fluctuate, and regression to the mean is a major issue in uncontrolled early trials.

AMT-260’s value will increase if multiple patients show durable reductions in seizure frequency, reduced antiseizure-medication burden and preserved cognitive function. Safety is also critical because the treatment requires direct brain delivery in patients who may otherwise consider established surgical options.

16. AMT-191 in Fabry disease

AMT-191 is a liver-directed AAV5 gene therapy carrying the GLA transgene under a potent liver-specific promoter. The objective is sustained production of alpha-galactosidase A, the enzyme deficient in Fabry disease.

Fabry disease is an X-linked lysosomal storage disorder characterized by accumulation of globotriaosylceramide and related substrates. Patients can develop kidney failure, cardiomyopathy, arrhythmia, neuropathic pain and stroke. Enzyme-replacement therapy requires repeated infusions and may not fully prevent organ progression.

Early AMT-191 data demonstrated large, dose-dependent increases in alpha-Gal A activity across eleven treated patients. As of February 18, 2026, all eleven dosed patients had been withdrawn from enzyme-replacement therapy. Enzyme expression appeared durable across follow-up ranging from several months to more than a year.

The safety picture is more complicated. Five serious adverse events had previously been reported in two patients at the highest dose. Additional dosing in mid- and high-dose cohorts was paused after two mid-dose patients developed asymptomatic Grade 3 liver-enzyme elevations confirmed as dose-limiting toxicities.

The program therefore demonstrates strong biological activity but has not established an optimal dose. If a lower dose can maintain sufficient enzyme activity without significant liver toxicity, AMT-191 could remain competitive. If high expression requires a dose with unacceptable hepatotoxicity, the program’s value may be limited despite impressive laboratory numbers.

17. AMT-162 discontinuation and what it teaches

AMT-162 was an intrathecal gene therapy designed to lower SOD1 in patients with SOD1-mutated amyotrophic lateral sclerosis. uniQure licensed the program from Apic Bio and initiated the EPISOD1 Phase I/II study.

Enrollment was voluntarily paused in 2025 after an independent monitoring review identified a serious adverse event that qualified as a dose-limiting toxicity in the second cohort. After review of preliminary safety and efficacy data from the five treated patients, uniQure discontinued development in 2026.

The discontinuation removes a potentially expensive program with weak risk-adjusted prospects. It also demonstrates that not every gene-silencing construct or intrathecal AAV strategy will produce a workable therapeutic window. For investors, AMT-162 should be excluded from forward pipeline value and retained only as a reminder of platform risk.

18. Competitive landscape in Huntington’s disease

The Huntington’s field includes multiple approaches to lower huntingtin or modify disease biology. Antisense oligonucleotides, RNA interference, small molecules, allele-selective strategies and other gene therapies are being explored.

Roche and Ionis experienced a major setback with tominersen when a Phase III program was stopped for unfavorable benefit-risk, although revised lower-frequency strategies continued to be investigated. Wave Life Sciences is developing allele-selective oligonucleotides intended to lower mutant huntingtin while preserving wild-type protein. Other companies are exploring orally available splicing modulators or different RNA-targeting technologies.

AMT-130’s differentiation is durability. A one-time treatment could avoid repeated lumbar punctures or chronic dosing. Its disadvantages are neurosurgery, irreversible exposure and non-selective huntingtin lowering.

If approved first, AMT-130 could establish treatment centers and physician familiarity before competitors mature. However, a later therapy with safer administration, allele selectivity or stronger randomized evidence could challenge adoption. Commercial success therefore depends not only on first approval but on durability, real-world benefit and the competitive timeline.

19. Catalyst map

20. Bull, base and bear scenarios

21. Risk matrix

22. What would strengthen the story?

• Written FDA alignment on a feasible confirmatory study without sham surgery.
• On-time Q3 2026 BLA and UK MAA submissions.
• FDA filing acceptance and priority review.
• Continued separation from natural-history controls at longer follow-up.
• Stable or improving TFC, motor and cognitive components—not only the composite endpoint.
• No new serious neurological safety signals.
• Clear commercial-center strategy and realistic treatment capacity.
• AMT-260 seizure reductions replicated across multiple patients.
• AMT-191 dose selection that preserves enzyme expression without Grade 3 liver toxicity.
• Cash burn that remains compatible with second-half 2029 runway.

23. What would weaken the story?

• Another FDA reversal or inability to align on the confirmatory design.
• BLA delay, refuse-to-file or requirement for a conventional randomized pivotal study before approval.
• Longer-term AMT-130 results converging toward natural-history progression.
• Evidence that the external-control matching was unstable or overly sensitive to assumptions.
• New neuroinflammation, procedure-related or delayed huntingtin-lowering safety problems.
• Manufacturing comparability issues in the commercial BLA package.
• Slower center activation or patient reluctance toward neurosurgery.
• AMT-260 efficacy failing to reproduce beyond the first patient.
• AMT-191 unable to find a safe and effective dose.
• Launch and confirmatory spending materially shortening the runway.

24. Evergreen checklist: how to read every QURE headline

The first question is whether the news changes the probability of BLA filing, acceptance or approval. Regulatory language must be read literally. “Acceptable as the primary basis” is not the same as “sufficient for approval.” “Plans to submit” is not the same as “submitted.” “BLA submitted” is not the same as “accepted for review.”

The second question is whether the confirmatory study is operationally realistic. A design that satisfies FDA but cannot enroll patients after commercial availability may create future risk. Investors should monitor number of sites, eligibility criteria, control structure, patient willingness and whether treatment access competes with trial enrollment.

The third question is durability. AMT-130 is a one-time therapy. The investment case improves if separation from natural history persists or widens over four and five years. It weakens if the benefit decays after the three-year analysis.

The fourth question is clinical meaningfulness. A percentage slowing sounds powerful, but readers should examine absolute change in cUHDRS, TFC and individual domains. A statistically persuasive difference must also translate into preserved independence and function.

The fifth question is commercial scalability. A neurosurgical gene therapy can command a high price, but treatment capacity is limited. The pace of patient referral, payer approval and center throughput will determine whether the theoretical market becomes revenue.

The sixth question is balance-sheet discipline. uniQure has enough capital to pursue the filing and launch. Management must avoid converting a strong runway into an oversized commercial infrastructure before regulatory risk is resolved.

25. Merlintrader assessment

uniQure is one of the most unusual regulatory special situations in biotechnology. The core data did not change dramatically between March and June 2026, yet the perceived approval path changed from years of additional development to a Q3 BLA plan. That makes QURE both attractive and dangerous.

The attractive part is clear. Huntington’s disease has no approved disease-modifying therapy. AMT-130 has generated multi-year evidence consistent with substantial slowing of progression. The program has RMAT, Breakthrough Therapy, Fast Track and Orphan designations. FDA now says the three-year analysis can serve as primary BLA evidence. The company has nearly $600 million in cash and securities and does not need an emergency financing to reach the decision window.

The dangerous part is equally clear. The dataset is small and externally controlled. FDA already rejected the same broad evidentiary concept once, then reversed. The confirmatory study remains unresolved. The product requires brain surgery and permanently lowers both mutant and wild-type huntingtin. Manufacturing, center readiness, long-term safety and payer acceptance remain untested at commercial scale.

AMT-130 is not a conventional late-stage biotech asset. It is closer to a regulatory negotiation built around compelling but nontraditional evidence in a disease with extreme unmet need. The approval probability cannot be inferred from designations alone. The exact wording of FDA correspondence and the quality of the final BLA will matter more than promotional summaries.

The secondary pipeline adds value but does not currently diversify the risk enough to protect the stock from an AMT-130 failure. AMT-260 is intriguing, especially if seizure reduction replicates across the first cohort. AMT-191 shows that uniQure can generate extraordinary transgene expression, but its liver-safety profile needs resolution. AMT-162 is discontinued. HEMGENIX provides credibility, not enough economics to support the company alone.

The balanced conclusion is that uniQure has one of the strongest potential near-term CNS gene-therapy opportunities and one of the most unstable regulatory narratives. A successful filing and approval could establish the first treatment shown to slow Huntington’s disease and transform the company. Another regulatory reversal could erase the current accelerated timeline and reprice the stock toward a much longer development scenario.

26. Update log